SCHEMBL29599669

SCHEMBL29599669

Cc1cc(CCC(=O)O)sc1C1(C)OCCO1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP26A1 O43174 3/20 0.40
CYP26B1 Q9NR63 3/20 0.40
NPSR1 Q6W5P4 1/20 0.40
RXRA P19793 2/20 0.35
FFAR1 O14842 4/20 0.34
S1PR1 P21453 2/20 0.34
S1PR3 Q99500 1/20 0.33
RXRB P28702 1/20 0.32
RXRG P48443 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
PRNP P04156 1/20 0.32
RECQL P46063 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
SLC22A12 Q96S37 2/20 0.32
RPS6KB2 Q9UBS0 1/20 0.32
HDAC6 Q9UBN7 1/20 0.31
CYP3A4 P08684 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29599437 0.78 STING1 (0.36) RXRARXRBRXRGSLC22A12
SCHEMBL29088420 0.77 CYP26A1 (0.36) CYP26A1RXRARXRBRXRGCYP3A4
SCHEMBL29600076 0.75 LMNA (0.43) CYP26A1CYP26B1NPSR1RXRAFFAR1
SCHEMBL29600056 0.73 HDAC6 (0.39) CYP26A1CYP26B1NPSR1ALDH1A1HDAC6
SCHEMBL1827179 0.73 NPSR1 (0.52) NPSR1FFAR1ALDH1A1LMNAPRNP
SCHEMBL29599237 0.72 CYP26B1 (0.41) CYP26A1CYP26B1NPSR1RXRAFFAR1
SCHEMBL29599886 0.69 HDAC6 (0.37) CYP26A1CYP26B1NPSR1RXRAFFAR1
SCHEMBL22870152 0.68 BACE1 (0.30)
SCHEMBL1824382 0.66 HPGD (0.50) NPSR1RXRAFFAR1RXRBRXRG
SCHEMBL22870391 0.65 ALDH1A1 (0.36) CYP26A1ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552757-B2 NRF2-activating compound SENJU PHARMACEUTICAL CO., LTD. (JP) 2026-02-17 US disclosed
US-20240132519-A1 NRF2-ACTIVATING COMPOUND SENJU PHARMACEUTICAL CO., LTD. (JP) 2024-04-25 US disclosed
EP-4273145-A1 NRF2-ACTIVATING COMPOUND Senju Pharmaceutical Co., Ltd. (JP) 2023-11-08 EP disclosed
US-20230024995-A1 NRF2-ACTIVATING COMPOUND SENJU PHARMACEUTICAL CO., LTD. (JP) 2023-01-26 US disclosed
EP-3998262-A1 NRF2-ACTIVATING COMPOUND Senju Pharmaceutical Co., Ltd. (JP) 2022-05-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230024995-A1 NRF2-ACTIVATING COMPOUND NFE2L2, KEAP1, NFE2 CYP26A1 1192/4885CYP26B1 678/4885NPSR1 2288/4885
US-12552757-B2 NRF2-activating compound NFE2L2, NFE2, KEAP1 CYP26A1 2603/4885CYP26B1 2350/4885NPSR1 3646/4885
US-20240132519-A1 NRF2-ACTIVATING COMPOUND NFE2L2, KEAP1, NFE2 CYP26A1 757/4885CYP26B1 541/4885NPSR1 2904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.